High lot-to-lot consistency
Increased sensitivity and higher affinity
Animal-free production
Description:
Anti-DLL3, AlpHcAbs® Human antibody is designed for detecting human DLL3 specifically. Anti-DLL3, AlpHcAbs® Human antibody is recombinant VHH domain of alpaca IgG2b/2c fused to Human IgG1 Fc. Based on ELISA, Anti-DLL3, AlpHcAbs® Human antibody reacts with human DLL3, and has reactivity with cynomolgus DLL3.
Immunogen: Recombinant human DLL3
Host: Alpaca pacous
Isotype: VHH domain of alpaca IgG2b/2c fused to Human IgG1 Fc(mutation)
Conjugate: Unconjugated
Specificity: Human DLL3
Cross-Reactivity: Cross-reactivity with cynomolgus DLL3
Purity: Recombinant Expression and Affinity purified
Concentration: 1mg/ml
Formation: Liquid, 10mM PBS (pH 7.5), 0.05% sucrose, 0.1% trehalose, 0.01% proclin300, 50% Glycerol
Storage: Store at –20 °C, (Avoid freeze / thaw cycles), Stable for 12 months at -20°C
Background:
Delta-like protein 3(DLL3) is a ligand for the Notch signaling pathway. It inhibits primary neurogenesis. DLL3 plays a role in the formation of somite boundaries during segmentation of the paraxial mesoderm. Defects in DLL3 are the cause of Spondylocostal dysostosis autosomal recessive type 1 (SCDO1). Mutations in DLL3 gene cause truncal shortening relative to their limbs, which leads to abdominal protrusion, abnormal spinal curvature and sometimes a plagiocephaly-torticollis sequence. It may be required to divert neurons along a specific differentiation pathway.
Using antibody with Fc(mutation), the background from Fc receptors will be eliminated.
ELISA: 1:4,000-1:10000
Flow Cytometry：1:200-1:1000
Dilution factors are presented in the form of a range because the optimal dilution is a function of many factors, such as antigen density, permeability, etc. The actual dilution used must be determined empirically.
